Pancreatic carcinoma

New England Journal of Medicine

Volumn 326, Issue 7, 1992, Pages 455-465

  Warshaw, Andrew L ^a   Castillo, Carlos Fernández Del ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; DOXORUBICIN; FLUOROURACIL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; ONCOFETAL ANTIGEN; STREPTOZOCIN; TAMOXIFEN; TISSUE ANTIGEN; TUMOR MARKER; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; DIAGNOSIS; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ETIOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS BIOPSY; PANCREAS CARCINOMA; PANCREAS SCINTISCANNING; PANCREAS SURGERY; PRIORITY JOURNAL; REVIEW; PANCREAS TUMOR;

HUMAN; PANCREATIC NEOPLASMS;

EID: 0027118569     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199202133260706     Document Type: Review

References (187)

1. American Cancer Society. Cancer facts and figures 1991. Atlanta: American Cancer Society, 1991.
2. National Cancer Institute. Annual cancer statistics review 1973–1988. Bethesda, Md.: Department of Health and Human Services, 1991. (NIH publication no. 91–2789.)
3. Boyle P., Hsieh C.-C., Maisonneuve P., et al. Epidemiology of pancreas cancer (1988). Int J Pancreatol 1989; 5:327-346
4. Swedish Cancer Registry. Cancer incidence in Sweden 1988. Stockholm, Sweden: National Board of Health and Welfare, 1991.
5. Hirayama T. Epidemiology of pancreatic cancer in Japan. Jpn J Clin Oncol 1989; 19:208-215
6. Mack T.M., Yu M.C., Hanisch R., Henderson B.E. Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst 1986; 76:49-60.
7. Falk R.T., Pickle L.W., Fontham E.T., Correa P., Fraumeni J.F. Jr. Life-style risk factors for pancreatic cancer in Louisiana: a case–control study. Am J Epidemiol 1988; 128:324-336
8. Doll R., Peto R. Mortality in relation to smoking: 20 years#x0027; observations on male British doctors. BMJ 1976; 2:1525-1536
9. Farrow D.C., Davis S. Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol and coffee. Int J Cancer 1990; 45: 816-20.
10. Ghadirian P., Simard A., Baillargeon J. Tobacco, alcohol, and coffee and cancer of the pancreas. Cancer 1991; 67:2664-2670
11. Cuzick J., Babiker A.G. Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. Int J Cancer 1989; 43:415-421
12. Howe G.R., Jain M., Burch J.D., Miller A.B. Cigarette smoking and cancer of the pancreas: evidence from a population-based case–control study in Toronto, Canada. Int J Cancer 1991; 47:323-328
13. Rivenson A., Hoffmann D., Prokopczyk B., Amin S., Hecht S.S. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 1988; 48:6912-6917
14. Rao M.S. Animal models of exocrine pancreatic carcinogenesis. Cancer Metastasis Rev 1987; 6:665-676
15. Wynder E.L., Mabuchi K., Maruchi N., Fortner J.G. Epidemiology of cancer of the pancreas. J Natl Cancer Inst 1973; 50:645-667
16. Farrow D.C., Davis S. Diet and the risk of pancreatic cancer in men. Am J Epidemiol 1990; 132:423-431
17. Mills P.K., Beeson W.L., Abbey D.E., Fraser G.E., Phillips R.L. Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists. Cancer 1988; 61:2578-2585
18. Norell S.E., Ahlbom A., Erwald R., et al. Diet and pancreatic cancer: a case–control study. Am J Epidemiol 1986; 124:894-902.
19. Howe G.R., Jain M., Miller A.B. Dietary factors and risk of pancreatic cancer: results of a Canadian population-based case–control study. Int J Cancer 1990; 45:604-608
20. Gold E.B., Gordis L., Diener M.D., et al. Diet and other risk factors for cancer of the pancreas. Cancer 1985; 55:460-467
21. Burney P.G., Comstock G.W., Morris J.S. Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. Am J Clin Nutr 1989; 49:895-900.
22. Longnecker D.S., Roebuck B.D., Kuhlmann E.T. Enhancement of pancreatic carcinogenesis by a dietary unsaturated fat in rats treated with saline or N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine. J Natl Cancer Inst 1985; 74:219-222
23. Birt D.F., Stepan K.R., Pour P.M. Interaction of dietary fat and protein on pancreatic carcinogenesis in Syrian golden hamsters. J Natl Cancer Inst 1983; 71:355-360
24. MacMahon B., Yen S., Trichopoulos D., Warren K., Nardi G. Coffee and cancer of the pancreas. N Engl J Med 1981; 304:630-633
25. Gordis L. Consumption of methylxanthine-containing beverages and risk of pancreatic cancer. Cancer Lett 1990; 52:1-12.
26. Offerhaus G.J.A., Tersmette A.C., Tersmette K.W.F., Tytgat G.N.J., Hoedemaeker P.J., Vandenbroucke J.P. Gastric, pancreatic, and colorectal carcinogenesis following remote peptic ulcer surgery. Mod Pathol 1988; 1:352-356
27. Taylor P.R., Dowling R.H., Palmer T.J., et al. Induction of pancreatic tumours by long-term duodenogastric reflux. Gut 1989; 30:1596-1600
28. Smith J.P., Solomon T.E., Bagheri S., Kramer S. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci 1990; 35:1377-1384
29. Hyvarinen H., Partanen S. Association of cholecystectomy with abdominal cancers. Hepatogastroenterology 1987; 34:280-284
30. Fisher W.E., McCullough P.J., Ramo O.J., Bell R.H. Further studies of enhanced growth of pancreatic carcinoma in diabetes. J Surg Res 1990; 48:403-407
31. Thomas P.G., Augustine P., Ramesh H., Rangabashyam N. Observations and surgical management of tropical pancreatitis in Kerala and southern India. World J Surg 1990; 14:32-42.
32. Girard R.M., Dube S., Archambault A.P. Hereditary pancreatitis: report of an affected Canadian kindred and review of the disease. Can Med Assoc J 1981; 125:576-580
33. Haddock G., Carter D.C. Aetiology of pancreatic cancer. Br J Surg 1990; 77:1159-1166
34. Longnecker D.S., Kuhlmann E.T., Freeman D.H. Jr. Characterization of the elastase 1-simian virus 40 T-antigen mouse model of pancreatic carcinoma: effects of sex and diet. Cancer Res 1990; 50:7552-7554
35. Sumi C., Longnecker D.S., Roebuck B.D., Brinck-Johnsen T. Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine. Cancer Res 1989; 49:2332-2336
36. Robles-Diaz G., Diaz-Sanchez V., Mendez J.P., Altamirano A., Wolpert E. Low serum testosterone/dihydrotestosterone ratio in patients with pancreatic carcinoma. Pancreas 1987; 2:684-687
37. Fernández-del Castillo C., Robles-Díaz G., Díaz-Sánchez V., Altamirano A. Pancreatic cancer and androgen metabolism: high androstenedione and low testosterone serum levels. Pancreas 1990; 5:515-518
38. Mancuso T.F., el-Attar A.A. Cohort study of workers exposed to betanaphthylamine and benzidine. J Occup Med 1967; 9:277-285
39. Lin R.S., Kessler I.I. A multifactorial model for pancreatic cancer in man. JAMA 1981; 245:147-152
40. Cubilla A.L., Fitzgerald P.J. Tumors of the exocrine pancreas. Atlas of tumor pathology. 2nd series. Fascicle 19. Washington, D.C.: Armed Forces Institute of Pathology. 1984.
41. Morohoshi T., Held G., Kloppel G. Exocrine pancreatic tumors and their histological classification: a study based on 167 autopsy and 97 surgical cases. Histopathology 1983; 7:645-661
42. Nagai H., Kuroda A., Morioka Y. Lymphatic and local spread of T1 and T2 pancreatic cancer. Ann Surg 1986; 204:65-71.
43. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549-554
44. Grunewald K., Lyons J., Frohlich A., et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989; 43:1037-1041
45. Shibata D., Almoguera C., Forrester K., et al. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res 1990; 50:1279-1283
46. Quaife C.J., Pinkert C.A., Ornitz D.M., Palmiter R.D., Brinster R.L. Pancreatic ncoplasia induced by ras expression in acinar cells of transgenic mice. Cell 1987; 48:1023-1034
47. Kalser M.H., Barkin J., MacIntyre J.M. Pancreatic cancer: assessment of prognosis by clinical presentation. Cancer 1985; 56:397-402.
48. Lin A., Feller E.R. Pancreatic carcinoma as a cause of unexplained pancreatitis: report of ten cases. Ann Intern Med 1990; 113:166-167
49. Kohler H., Lankisch P.G. Acute pancreatitis and hyperamylasemia in pancreatic carcinoma. Pancreas 1987; 2:117-119
50. Rosa J.A., Van Linda B.M., Abourizk N.N. New-onset diabetes mellitus as a harbinger of pancreatic carcinoma. J Clin Gastroenterol 1989; 11:211-215
51. Bell E.T. Carcinoma of the pancreas. II. The relation of cancer of the pancreas to diabetes mellitus. Am J Pathol 1957; 33:511-523
52. Green R.C. Jr., Baggenstoss A.H., Sprague R.G. Diabetes mellitus in association with primary carcinoma of the pancreas. Diabetes 1958; 7:308-311
53. Nix G.A.J.J., Schmitz P.I.M., Wilson J.H.P., Van Blankenstein M., Groeneveld C.F.M., Hofwijk R. Carcinoma of the head of the pancreas: therapeutic implications of endoscopic retrograde cholangiopancreatography findings. Gastroenterology 1984; 87:37-43.
54. Ishikawa O., Ohhigashi H., Wada A., et al. Morphologic characteristics of pancreatic carcinoma with diabetes mellitus. Cancer 1989; 64:1107-1112
55. Pollock D., Taylor K.J.W. Ultrasound scanning in patients with clinical suspicion of pancreatic cancer. Cancer 1981; 47:1662-1665
56. Bernardino M.E., Barnes P.A. Imaging the pancreatic neoplasm. Cancer 1982; 50:Suppl II:2681-2688
57. Freeny P.C. Radiology of the pancreas: two decades of progress in imaging and intervention. AJR Am J Roentgenol 1988; 150:975-981
58. Steiner E., Stark D.D., Hahn P.F., et al. Imaging of pancreatic neoplasms: comparison of MR and CT. AJR Am J Roentgenol 1989; 152:487-491
59. Van Dyke J.A., Stanley R.J., Berland L.L. Pancreatic imaging. Ann Intern Med 1985; 102:212-217
60. Freeny P.C., Marks W.M., Ryan J.A., Traverso L.W. Pancreatic ductal adenocarcinoma: diagnosis and staging with dynamic CT. Radiology 1988; 166: 125-33.
61. Balthazar E.J., Chako A.C., et al. Computed tomography of pancreatic masses. Am J Gastroenterol 1990; 85:343-349
62. Taylor K.J.W., Rosenfield A.T. Grey-scale ultrasonography in the differential diagnosis of jaundice. Arch Surg 1977; 112:820-825
63. Lees W.R. Pancreatic ultrasonography. Clin Gastroenterol 1984; 13:763-789
64. Togawa Y., Fujimoto S., Okui K. The diagnostic accuracy of magnetic resonance imaging in pancreatic carcinoma based on a retrospective analysis of vascular involvement. Jpn J Surg 1989; 19:398-402.
65. McCune W.S., Shorb P.E., Moscovitz H. Endoscopic cannulation of the ampulla of vater: a preliminary report. Ann Surg 1968; 167:752-756
66. Michelassi F., Erroi F., Dawson P.J., et al. Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct. Ann Surg 1989; 210:544-554
67. Tarazi R.Y., Hermann R.E., Vogt D.P., et al. Results of surgical treatment of periampullary tumors: a thirty-five-year experience. Surgery 1986; 100: 716-23.
68. Freeny P.C. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Radiol Clin North Am 1989; 27:121-128
69. Shemesh E., Czerniak A., Nass S., Klein E. Role of endoscopic retrograde cholangiopancreatography in differentiating pancreatic cancer coexisting with chronic pancreatitis. Cancer 1990; 65:893-896
70. Endo Y., Morii J., Tamura N., Okuda S. Cytodiagnosis of pancreatic malignant tumors by aspiration, under direct vision, using a duodenal fiberscope. Gastroenterology 1974; 67:944-951
71. Venu R.P., Geenen J.E., Kini M., et al. endoscopic retrograde brush cytology: a new technique. Gastroenterology 1990; 99:1475-1479
72. Scudera P.L., Koizumi J., Jacobson I.M. Brush cytology evaluation of lesions encountered during ERCP. Gastrointest Endose 1990; 36:281-284
73. Sawada Y., Gonda H., Hayashida Y. Combined use of brushing cytology and endoscopic retrograde pancreatography for the early detection of pancreatic cancer. Acta Cytol 1989; 33:870-874
74. Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol 1990; 85:350-355
75. Steinberg W.M., Gelfand R., Anderson K.K., et al. Comparison of the sensitivity and specificity of the CA 19–9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986; 90:343-349
76. Pleskow D.K., Berger H.J., Gyves J., Allen E., McLean A., Podolsky D.K. Evaluation of a serologic marker, CA 19–9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110:704-709
77. Meduri F., Doni M.G., Merenda R., et al. The role of the leukocyte adherence inhibition (LAI), CA 19–9, and tissue polypeptide antigen (TPA) tests in the diagnosis of pancreatic cancer. Cancer 1989; 64:1103-1106
78. Panucci A., Fabris C., Del Favero G., et al. Tissue polypeptide antigen (TPA) in pancreatic cancer diagnosis. Br J Cancer 1985; 52:801-803
79. Nishida K., Sugiura M., Yoshikawa T., Kondo M. Enzyme immunoassay of pancreatic oncofetal antigen (POA) as a marker of pancreatic cancer. Gut 1985; 26:450-455
80. Mahvi D.M., Seigler H.F., Meyers W.C., Kalthoff H., Schmiegel W.H., Metzgar R.S. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. Pancreas 1988; 3:488-493
81. Podolsky D.K., McPhee M.S., Alpert E., Warshaw A.L., Isselbacher K.J. Galactosyltransferase isoenzyme II in the detection of pancreatic cancer: comparison with radiologic, endoscopic, and serologic tests. N Engl J Med 1981; 304:1313-1318
82. Warshaw A.L., Lee K.-H., Wood W.C., Cohen A.C., et al. Sensitivity and specificity of serum ribonuclease in the diagnosis of pancreatic cancer. Am J Surg 1980; 139:27-32.
83. Del Favero G., Basso D., Fabris C., et al. Ribonucleases and deoxyribonucleases in pancreatic cancer: clinical value and pathophysiological interrelationships. Int J Pancreatol 1988; 3:Suppl 1:S107-S112.
84. Hamano H., Hayakawa T., Kondo T. Serum immunoreactive elastase in diagnosis of pancreatic diseases: a sensitive marker for pancreatic cancer. Dig Dis Sci 1987; 32:50-56
85. Gullo L., Pezzilli R., Ventrucci M., et al. Serum immunoreactive elastase: is it useful for the diagnosis of pancreatic cancer? Pancreas 1989; 4:335-338
86. Robles-Díaz G., Díaz-Sánchez V., Fernández-del Castillo C., et al. Serum testosterone:dihydrotestosterone ratio and CA 19–9 in the diagnosis of pancreatic cancer. Am J Gastroenterol 1991; 86:591-594
87. Frebourg T., Bercoff E., Manchon N., et al. The evaluation of CA 19–9 antigen level in the early detection of pancreatic cancer. Cancer 1988; 62: 2287-90.
88. Glenn J., Steinberg W.M., Kurtzman S.H., Steinberg S.M., Sindelar W.F. Evaluation of the utility of a radioimmunoassay for serum CA 19–9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988; 6:462-468
89. Fabris C., Del Favero G., Basso D., et al. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastative approach. Am J Gastroenterol 1988; 83:549-553
90. Warshaw A.L., Swanson R.S. Pancreatic cancer in 1988: possibilities and probabilities. Ann Surg 1988; 208:541-553
91. Athlin L., Blind P.J., Angstrom T. Fine-needle aspiration biopsy of pancreatic masses. Acta Chir Scand 1990; 156:91-94
92. Parsons L., Palmer C.H. How accurate is fine-needle biopsy in malignant neoplasia of the pancreas? Arch Surg 1989; 124:681-683
93. DelMaschio A., Vanzulli A., Sironi S., et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19–9 assessment, US, CT, and CT-guided fine-needle biopsy. Radiology 1991; 178:95-99
94. Al-Kaisi N., Siegler E.E. Fine needle aspiration cytology of the pancreas. Acta Cytol 1989; 33:145-152
95. Fernández-del Castillo C., González-Ojeda A., Reyes E., Quiróz-Ferrari F., Uribe M., Robles-Díaz G. Tuberculosis of the pancreas. Pancreas 1990; 5: 693-6.
96. Essop A.R., Posen J., Path F.F., Segal I., Pantanowitz D. Isolated granulomatous pancreatitis. J Clin Gastroenterol 1984; 6:61-64
97. Webb T.H., Lillemoe K.D., Pitt H.A., Jones R.J., Cameron J.L. Pancreatic lymphoma: is surgery mandatory for diagnosis or treatment? Ann Surg 1989; 209:25-30.
98. Hart M.J., White T.T., Brown P.C., Freeny P.C. Potentially curable masses in the pancreas. Am J Surg 1987; 154:134-136
99. Warshaw A.L., Compton C.C., Lewandrowski K., Cardenosa G., Mueller P.R. Cystic tumors of the pancreas: new clinical, radiologic, and pathologic observations in 67 patients. Ann Surg 1990; 212:432-445
100. Eckhauser F.E., Cheung P.S., Vinik A.I., Strodel W.E., Lloyd R.V., Thompson N.W. Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 1986; 100:978-987
101. Ferrucci J.T., Wittenberg J., Margolies M.N., Carey R.W. Malignant seeding of the tract after thin-needle aspiration biopsy. Radiology 1979; 130:345-346
102. Rashleigh-Belcher H.J.C., Russell R.C.G., Lees W.R. Cutaneous seeding of pancreatic carcinoma by fine-needle aspiration biopsy. Br J Radiol 1986; 59:182-183
103. Weiss S.M., Skibber J.M., Mohiuddin M., Rosato F.E. Rapid intra-abdominal spread of pancreatic cancer. Arch Surg 1985; 120:415-416
104. Warshaw A.L. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991; 161:26-30.
105. Whittington R., Dobelbower R.R., Mohiuddin M., Rosato F.E., Weiss S.M. Radiotherapy of unresectable pancreatic carcinoma: a six year experience with 104 patients. Int J Radiat Oncol Biol Phys 1981; 7:1639-1644
106. Gooding G.A.W. Nuclear imaging of the pancreas. In: Howard JM, Jordan GL Jr, Reber HA, eds. Surgical diseases of the pancreas. Philadelphia: Lea & Febiger, 1987: 101-4.
107. Yamamoto K., Shibata T., Saji H., et al. Human pancreas scintigraphy using iodine-123-labeled HIPDM and SPECT. J Nucl Med 1990; 31:1015-1019
108. Baum R.P. Immunoscintigraphy as a diagnostic tool in pancreatic cancer. Hepatogastroenterology 1989; 36:459-461
109. Erratum, Hepatogastroenterology 1990; 37:154.
110. Worlock A.J., Zalutsky M.R., Metzgar R.S. Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. Cancer Res 1990; 50:7246-7251
111. Tsuda T., Koshiba H., Usui T., Kubota M., Kikuchi K., Monta K. Radioimmunoscintigraphy of human pancreatic carcinoma xenografts in nude mice with 131I-labeled monoclonal antibody. Ann Nucl Med 1990; 4:71-74
112. Tio T.L., Tytgat G.N.J. Cikot RJLM, Houthoff HJ, Sars PRA. Ampullopancreatic carcinoma: preoperative TNM classification with endosonography. Radiology 1990; 175:455-461
113. Hayashi Y., Nakazawa S., Kimoto E., Naito Y., Morita K. Clinicopathologic analysis of endoscopic ultrasonograms in pancreatic mass lesions. Endoscopy 1989; 21:121-125
114. Kaufman A.R., Sivak M.V. Jr. Endoscopic ultrasonography in the differential diagnosis of pancreatic disease. Gastrointest Endose 1989; 35:214-219
115. Mukai H., Mizuno S., Hayakumo T., Yasuda K., Nakajima M. Clinical evaluation of an ultrasonic probe in the diagnosis of biliary and pancreatic tumors. Gastrointest Endose 1991; 37:275. abstract.
116. Rosenberg J.M., Welch J.P., Macaulay W.P. Cancer of the head of the pancreas: an institutional review with emphasis on surgical therapy. J Surg Oncol 1985; 28:217-221
117. Connolly M.M., Dawson P.J., Michelassi F., Moosa A.R., Lowenstein F. Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 1987; 206:366-373
118. Craighead C.C., Lien R.C. Pancreatoduodenal resection: comments on indications, operative diagnosis, staged procedures, morbid and lethal factors, and survivals. Ann Surg 1958; 147:931-934
119. Crist D.W., Sitzmann J.V., Cameron J.L. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987; 206:358-365
120. Grace P.A., Pitt H.A., Tompkins R.K., DenBesten L., Longmire W.P. Decreased morbidity and mortality after pancreatoduodenectomy. Am J Surg 1986; 151:141-148
121. Braasch J.W., Rossi R.L., Watkins E. Jr., Deziel D.J., Winter P.F. Pyloric and gastric preserving pancreatic resection. Ann Surg 1986; 204:411-418
122. Trede M., Schwall G., Saeger H.D. Surviva! after pancreatoduodenectomy. Ann Surg 1990; 211:447-458
123. Huibregtse K., Katon R.M., Coene P.P., Tytgat G.N.J. Endoscopic palliative treatment in pancreatic cancer. Gastrointest Endose 1986; 32:334-338
124. Speer A.G., Cotton P.B., Russell R.C.G., et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2:57-62.
125. Andersen J.R., Sørensen S.M., Kruse A., Rokkjaer M., Matzen P. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989; 30:1132-1135
126. Beahrs O.H., Henson D.E., Hutter R.V.P., Myers M.H., eds. Manual for staging of cancer. 3rd ed. Philadelphia: J.B. Lippincott, 1988.
127. Warshaw A.L., Gu Z.-Y., Wittenberg J. Waltman ACPreoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 1990; 125: 230-3.
128. Mackie C.R., Noble H.G., Cooper M.J., Collins P., Block G.E., Moossa A.R. Prospective evaluation of angiography in the diagnosis and management of patients suspected of having pancreatic cancer. Ann Surg 1979; 189:11-17
129. Rong G.H., Sindelar W.F. Aberrant peripancreatic arterial anatomy: considerations in performing pancreatectomy for malignant neoplasms. Am Surg 1987; 53:726-729
130. Cubilla A.L., Fitzgerald P.J., Former J.G. Pancreas cancer — duct cell adenocarcinoma: survival in relation to site, size, stage and type of therapy. J Surg Oncol 1978; 10:465-482
131. Ward E.M., Stephens D.H., Sheedy P.F. II. Computed tomographic characteristics of pancreatic carcinoma: an analysis of 100 cases. Radiographies 1983; 3:547-565
132. Warshaw A.L., Tepper J.E., Shipley W.U. Laparoscopy in the staging and planning of therapy for pancreatic cancer. Am J Surg 1986; 151:76-80.
133. Cuschieri A. Laparoscopy for pancreatic cancer: does it benefit the patient? Eur J Surg Oncol 1988; 14:41-44
134. Tsuchiya R., Noda T., Harada M., et al. Collective review of small carcinomas of the pancreas. Ann Surg 1986; 203:77-81.
135. Pellegrini C.A., Heck C.F., Raper S., Way L.W. An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy. Arch Surg 1989; 124:778-781
136. Baisch H., Klöppel G., Reinke B. DNA ploidy and cell-cycle analysis in pancreatic and ampullary carcinoma: flow cytometric study of formalin-fixed paraffin-embedded tissue. Virchows Archiv [A] 1990; 417:145-150
137. Alanen K.A., Joensuu H., Klemi P.J., Nevalainen T.J. Clinical significance of nuclear DNA content in pancreatic carcinoma. J Pathol 1990; 160:313-320
138. Weger A.R., Glaser K.S., Schwab G., et al. Quantitative nuclear DNA content in fine needle aspirates of pancreatic cancer. Gut 1991; 32:325-328
139. Eskelinen M., Lipponen P., Collan Y., Marin S., Alhava E., Nordling S. Relationship between DNA ploidy and survival in patients with exocrine pancreatic cancer. Pancreas 1991; 6:90-95
140. Allison D.C., Bose K.K., Hruban R.H., et al. Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy. Ann Surg 1991; 214:648-656
141. Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer 1987; 60:2284-2303
142. Cameron J.L., Crist D.W., Sitzmann J.V., et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161:120-125
143. Gudjonsson B., Livstone E.M., Spiro H.M. Cancer of the pancreas: diagnostic accuracy and survival statistics. Cancer 1978; 42:2494-2506
144. van Heerden J.A. Pancreatic resection for carcinoma of the pancreas: Whipple versus total pancreatectomy — an institutional perspective. World J Surg 1984; 8:880-888
145. Blumberg N., Chuang-Stein C., Heal J.M. The relationship of blood transfusion, tumor staging, and cancer recurrence. Transfusion 1990; 30:291-294
146. ReMine W.H., Priestley J.T., Judd E.S., King J.N. Total pancreatectomy. Ann Surg 1970; 172:595-604.
147. Brooks J.R., Brooks D.C., Levine J.D. Total pancreatectomy for ductal cell carcinoma of the pancreas: an update. Ann Surg 1989; 209:405-410
148. van Heerden J., ReMine W.H., Weiland L.H., McIlrath D.C., Ilstrup D.M. Total pancreatectomy for ductal adenocarcinoma of the pancreas. Am J Surg 1981; 142:308-311
149. Andrén-Sandberg A., Ihse I. Factors influencing survival after total pancreatectomy in patients with pancreatic cancer. Ann Surg 1983; 198:605-610
150. Fortner J.G. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Ann Surg 1984; 199:418-425
151. Ishikawa O., Ohhigashi H., Sasaki Y., et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988; 208:215-220
152. Tsuchiya R., Tsunoda T., Yamaguchi T. Operative of choice for resectable carcinoma of the head of the pancreas. Int J Pancreatol 1990; 6:295-306.
153. Grace P.A., Pitt H.A., Longmire W.P. Pylorus preserving pancreatoduodenectomy: an overview. Br J Surg 1990; 77:968-974
154. Sharp K.W., Ross C.B., Halter S.A., et al. Pancreatoduodenectomy with pyloric preservation for carcinoma of the pancreas: a cautionary note. Surgery 1989; 105:645-653
155. Boerma E.J., Coosemans J.A.R. Non-preservation of the pylorus in resection of pancreatic cancer. Br J Surg 1990; 77:299-300.
156. Funovics J.M., Karner J., Pratschner T., Fritsch A. Current trends in the management of carcinoma of the pancreatic head. Hepatogastroenterology 1989; 36:450-455
157. Singh S.M., Longmire W.P. Jr., Reber H.A. Surgical palliation for pancreatic cancer: the UCLA experience. Ann Surg 1990; 212:132-139
158. Sarr M.G., Cameron J.L. Surgical management of unresectable carcinoma of the pancreas. Surgery 1982; 91:123-133
159. Soehendra N., Grimm H., Berger B., Nam V.C. Malignant jaundice: results of diagnostic and therapeutic endoscopy. World J Surg 1989; 13:171-177
160. Smith AC, Dowsett J.F., Hatfield A.R.W., et al. Prospective randomised trial of bypass surgery v endoscopic stenting in patients with malignant obstructive jaundice. Gut 1989; 30:A1513. abstract.
161. Doberneck R.C., Berndt G.A. Delayed gastric emptying after palliative gastrojejunostomy for carcinoma of the pancreas. Arch Surg 1987; 122:827-829
162. Weaver D.W., Wiencek R.G., Bouwman D.L., Walt A.J. Gastrojejunostomy: is it helpful for patients with pancreatic cancer? Surgery 1987; 102:608-613
163. Moertel C.G., Childs D.S., Reitemeier R.J., Colby M.Y., Holbrook M. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2:865-867
164. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5 fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981; 48:1705-1710
165. Dobelbower R.R. Jr., Konski A.A., Merrick H.W. III, Bronn D.G., Schifeling D., Kamen C. Intraoperative electron beam radiation therapy (IOEBRT) for carcinoma of the exocrine pancreas. Int J Radiat Oncol Biol Phys 1991; 20:113-119
166. Heijmans H.J., Hoekstra H.J., Mehta D.M. Is adjuvant intra-operative radiotherapy (IORT) for resectable and unresectable pancreatic carcinoma worthwhile? Hepatogastroenterology 1989; 36:474-477
167. Shipley W.U., Wood W.C., Tepper J.E., et al. Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg 1984; 200:289-294
168. Roldan G.E., Gunderson L.L., Nagorney D.M., et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 1988; 61:1110-1116
169. Merrick H.W. III, Dobelbower R.R. Jr. Aggressive therapy for cancer of the pancreas: does it help? Gastroenterol Clin North Am 1990; 19:935-962
170. Joyce F., Burcharth F., Holm H.H., Stroyer I. Ultrasonically guided percutaneous implantation of Iodine-125 seeds in pancreatic carcinoma. Int J Radiat Oncol Biol Phys 1990; 19:1049-1052
171. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59:2006-2010
172. Wils J.A. Current status of chemotherapy in metastatic pancreatic cancer. Anticancer Res 1989; 9:1027-1032
173. Arbuck S.G. Overview of chemotherapy for pancreatic cancer. Int J Pancreatol 1990; 7:209-222
174. Mallinson C.N., Rake M.O., Cocking J.B., et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. BMJ 1980; 281:1589-1591
175. Wagener D.J.T., van Hoesel Q.G.C.M., Yap S.H., Hoogenraad W.J., Wobbes T., Strijk S.P. Phase trial of 5-fluorouracil, adriamycin and cisplatin (FAP) followed by radiation and 5-fluorouracil in locally advanced pancreatic cancer. Cancer Chemother Pharmacol 1989; 25:131-134
176. Greenway B.A. Carcinoma of the exocrine pancreas: a sex hormone responsive tumor? Br J Surg 1987; 74:441-442
177. Keating J.J., Johnson P.J., Cochrane A.M.G., et al. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 1989; 60:789-792
178. Bakkevold K.E., Pettersen A., Arnesjo B., Espehaug B. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 1990; 77:725-730
179. Wong A., Chan A., Arthur K. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep 1987; 71:749-750
180. Szende B., Srkalovic G., Groot K., Lapis K., Schally A.V. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists. Cancer Res 1990; 50: 3716-21.
181. Gonzalez-Barcena D., Ibarra-Olmos M.A., Garcia-Carrasaco F., Gutierrez-Samperio C., Comaru-Schally A.M., Schally A.V. Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed Pharmacother 1989; 43:313-317
182. Andren-Sandberg A. Treatment with an LHRH analogue in patients with advanced pancreatic cancer. Acta Chir Scand 1990; 156:549-551
183. Fekete M., Zalatnai A., Schally A.V. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer. Cancer Lett 1989; 45:87-91.
184. Mang T.S., Wieman T.J. Photodynamic therapy in the treatment of pancreatic carcinoma: dihematoporphyrin ether uptake and photobleaching kinetics. Photochem Photobiol 1987; 46:853-858
185. Schroder T., Chen I.-W., Sperling M., Bell R.H. Jr., Brackett K., Joffe S.N. Hematoporphyrin derivative uptake and photodynamic therapy in pancreatic carcinoma. J Surg Oncol 1988; 38:4-9.
186. Mehta M.P., Kubsad S.S., Fowler J.F., Verma A.K., Hsieh J.-T., Kinsella T.J. 90Y.B72.3 against pancreatic cancer: dosimetric and biological analysis. Int J Radiat Oncol Biol Phys 1990; 19:627-631
187. Tempero M.A., Sivinski C., Steplewski Z., Harvey E., Klassen L., Kay H.D. Phase II trial of interferon gamma and monoclonal antibody 17–1A in pancreatic cancer: biological and clinical effects. J Clin Oncol 1990; 8: 2019-26.